Wash U Team Looks to Expand on Initial Success of Sequencing in Breast Cancer Clinical Trial
April 05, 2011
Wash U Team Looks to Expand on Initial Success of Sequencing in Breast Cancer Clinical Trial
The Wash U researchers sequenced 50 tumor/normal breast cancer pairs in order to gain insight into the mechanisms that underlie resistance to aromatase inhibitor therapy. They plan to use the same approach in another trial that is studying trastuzumab plus chemotherapy in HER2-positive breast cancer.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Wash U Team Aims to Develop Sequencing-Based Individualized Vaccines for Breast Cancers
April 26, 2011 / Clinical Sequencing News - Wash U Awarded $6.5M Grant to Develop Sequencing-Based Breast Cancer Vaccine
April 19, 2011 / Clinical Sequencing News - Sequencing, Though Not Always a Slam Dunk, Gains Traction in Genomic Medicine
March 13, 2013 / Clinical Sequencing News - Sequencing Studies Lead to New Clinical Trial for Overlooked HER2 Mutations in Breast Cancer
December 12, 2012 / Clinical Sequencing News - WGS IDs Markers of Response to Aromatase Inhibitors; New Trial Will Use Signatures to Guide Treatment
June 13, 2012 / Clinical Sequencing News